Observational studyThe Journal of clinical endocrinology and metabolism2025
Clinical Features, Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome).
Observational study in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and metabolic characteristics of acquired partial lipodystrophy: insights from a multicenter study.Journal of endocrinological investigation · 2026Article
- Liver Lipodystrophy in Barraquer-Simons Syndrome: How Much Should We Worry About?Life (Basel, Switzerland) · 2026Article
- Clinical Features, Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome).The Journal of clinical endocrinology and metabolism · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
contextAcquired partial lipodystrophy (APL) is an ultra-rare disorder characterized by unique loss of subcutaneous fat affecting mostly the face, neck, trunk, and upper extremities. The precise prevalence of metabolic derangements and other comorbidities among patients with APL is not clear.
objectiveWe report clinical features and metabolic and autoimmune derangements in a large cohort.
methodsA total of 86 participants (77 female, 9 male; median age 40 years [range 8-78 years]) with APL from 2 US tertiary referral centers, UT Southwestern and National Institute of Diabetes and Digestive and Kidney Diseases, were recruited into prospective observational studies. Demographic, health history, and laboratory data at the initial evaluation and follow-up were systematically collected and analyzed.
resultsThe median age of onset of lipodystrophy was 7 years (range, 2-51 years). About 15% had autoimmune diseases, 38% had either diabetes mellitus or glucose intolerance, 43% had hypertriglyceridemia, and 61% had fatty liver or metabolic dysfunction-associated steatohepatitis (MASH). A total of 71% of patients had low serum complement 3 (C3) levels, 8% had membranoproliferative glomerulonephritis, while drusen occurred in 62% of those with fundus examination (n = 21). Patients with C3 hypocomplementemia, compared to those with normal serum C3 level, reported earlier onset of diabetes or glucose intolerance (median age 36 vs 56.5 years, P = .007), hypertriglyceridemia (30 vs 48 years, P = .03), and drusen (33 vs 60 years, P = .14).
conclusionOur data reveal high risk of metabolic comorbidities and drusen in patients with APL, with earlier onset of these complications in those with C3 hypocomplementemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.